Eli Lilly’s weight loss drug, tirzepatide, showed substantial potential in a large Phase 3 study, the results of which were reported on April 28th. If tirzepatide gets approved, it could become a blockbuster. But, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles.
Subscribe to:
Post Comments (Atom)
< + > Healthcare IT Failures – Healthcare IT Today Podcast Episode 195
For the 195th episode of the Healthcare IT Today Podcast , we are taking a look at healthcare IT failures! We kick this episode off by debat...
No comments:
Post a Comment